Liver Cancer Trial, Recruiting NCT06999837 Sponsor: Nantes University Hospital Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT06999837
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to give written consent to take part
  • You are 18 years old or older
  • For Group A: You have liver cancer (HCC) either confirmed by tissue sample or by scan results, and are scheduled for a biopsy; OR for Group B: You have known liver cancer and need new scans to check for disease that may have come back, not responded to treatment, or not been fully removed
  • You have at least one liver tumour that can be measured and tracked on a contrast scan (CT or MRI)
  • You are generally able to carry out daily activities with little or no restriction (a standard activity scale rated 0 to 2)
  • Your liver function falls within a certain acceptable range (known as Child-Pugh A — confirm with trial site)
  • Your doctor estimates you are expected to live at least 6 more months
  • You are covered by or eligible for the National Health Service
  • You agree to use two forms of contraception after receiving the study scan injection — for 6 months if you are a woman (and your partner), or 3 months if you are a man (and your partner)

Who may not be able to join:

  • You have a known allergy to the study imaging agent (PSMA-11) or to contrast dyes used in scans
  • You need emergency surgery because your liver cancer has burst or is bleeding
  • You have had a type of radiation treatment called radioembolization within the last 3 months
  • You have significant heart problems rated at a serious level (New York Heart Association class III or IV — confirm with trial site)
  • You have had major surgery within the last 4 weeks
  • You have or have had another type of cancer, unless it was completely removed skin cancer or cervical cancer in situ, or you have had no signs of it returning for at least 2 years
  • You have another serious uncontrolled health condition — such as an active infection (including HIV), unstable heart problems, uncontrolled high blood pressure, poorly controlled diabetes, or other significant medical or mental health issues that the doctor feels could affect your safety or ability to take part
  • You are pregnant or currently breastfeeding (a pregnancy test will be done at the start of the study for women who could become pregnant)
  • You are under legal guardianship or trusteeship
  • You are under court-ordered legal protection (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +33 2 40 08 41 36

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
23 September 2025
Est. completion
23 September 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Diagnostic performance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov